表紙
市場調査レポート

加齢黄斑変性症(AMD):パイプライン製品の分析

Age Related Macular Degeneration - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213105
出版日 ページ情報 英文 579 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
加齢黄斑変性症(AMD):パイプライン製品の分析 Age Related Macular Degeneration - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 579 Pages
概要

加齢黄斑変性症 (AMD) は、50歳以上の人の失明原因で最も一般的なものです。黄斑に障害が生じ、中心視野が歪んだり、ぼやけたりします。素因として、年齢、喫煙、太陽光、遺伝などが挙げられます。盲点、目のかすみなどの症状が見られます。治療は、光線力学的療法、放射線療法、薬物療法 (抗血管新生薬など) があります。ビタミンや食習慣の改善も、有効性が証明されています。

当レポートでは、加齢黄斑変性症 (AMD) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

加齢黄斑変性症 (AMD) の概要

治療薬の開発

加齢黄斑変性症 (AMD) :企業で開発中の治療薬

加齢黄斑変性症 (AMD) :大学/機関で研究中の治療薬

加齢黄斑変性症 (AMD) :パイプライン製品の概況

加齢黄斑変性症 (AMD) :企業で開発中の製品

加齢黄斑変性症 (AMD) :大学/機関で研究中の製品

加齢黄斑変性症 (AMD) の治療薬開発に従事している企業

加齢黄斑変性症 (AMD) :治療薬の評価

薬剤プロファイル

加齢黄斑変性症 (AMD) :最近のパイプライン動向

加齢黄斑変性症 (AMD) :休止中のプロジェクト

加齢黄斑変性症 (AMD) :開発が中止された製品

加齢黄斑変性症 (AMD) :製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7973IDB

Summary

Global Markets Direct's, 'Age Related Macular Degeneration - Pipeline Review, H1 2016', provides an overview of the Age Related Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
  • The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects
  • The report assesses Age Related Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Age Related Macular Degeneration Overview
  • Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics under Development by Companies
  • Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
  • Age Related Macular Degeneration - Pipeline Products Glance
  • Age Related Macular Degeneration - Products under Development by Companies
  • Age Related Macular Degeneration - Products under Investigation by Universities/Institutes
  • Age Related Macular Degeneration - Companies Involved in Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics Assessment
  • Drug Profiles
  • Age Related Macular Degeneration - Recent Pipeline Updates
  • Age Related Macular Degeneration - Dormant Projects
  • Age Related Macular Degeneration - Discontinued Products
  • Age Related Macular Degeneration - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Age Related Macular Degeneration, H1 2016
  • Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Age Related Macular Degeneration - Pipeline by AC Immune SA, H1 2016
  • Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Aciont Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by AdAlta Pty Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Alimera Sciences, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Allergan Plc, H1 2016
  • Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H1 2016
  • Age Related Macular Degeneration - Pipeline by Alteogen Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Amakem NV, H1 2016
  • Age Related Macular Degeneration - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Age Related Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016
  • Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Apexigen, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Benitec Biopharma Limited, H1 2016
  • Age Related Macular Degeneration - Pipeline by BIOCAD, H1 2016
  • Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by BioMAS Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Biophytis SAS, H1 2016
  • Age Related Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Age Related Macular Degeneration - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Age Related Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Charlesson LLC., H1 2016
  • Age Related Macular Degeneration - Pipeline by Cipla Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Clanotech AB, H1 2016
  • Age Related Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Age Related Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Company, H1 2016
  • Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Critical Pharmaceuticals Limited, H1 2016
  • Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Age Related Macular Degeneration - Pipeline by Delenex Therapeutics AG, H1 2016
  • Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Digna Biotech, S.L., H1 2016
  • Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS, H1 2016
  • Age Related Macular Degeneration - Pipeline by Exonate Limited, H1 2016
  • Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Formycon AG, H1 2016
  • Age Related Macular Degeneration - Pipeline by Gene Techno Science Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Genentech, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by GenSight Biologics S.A., H1 2016
  • Age Related Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016
  • Age Related Macular Degeneration - Pipeline by GTx, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Innovent Biologics, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Intellect Neurosciences, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by International Stem Cell Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H1 2016
  • Age Related Macular Degeneration - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Age Related Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Kodiak Sciences, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by LeadArtis S.L., H1 2016
  • Age Related Macular Degeneration - Pipeline by M's Science Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by Mabion SA, H1 2016
  • Age Related Macular Degeneration - Pipeline by MacuCLEAR, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Mitotech S.A., H1 2016
  • Age Related Macular Degeneration - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Navya Biologicals Pvt Ltd, H1 2016
  • Age Related Macular Degeneration - Pipeline by Neovacs SA, H1 2016
  • Age Related Macular Degeneration - Pipeline by Neumedicines Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H1 2016
  • Age Related Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Novartis AG, H1 2016
  • Age Related Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Omeros Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by Ophthotech Corp., H1 2016
  • Age Related Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Oxford BioMedica Plc, H1 2016
  • Age Related Macular Degeneration - Pipeline by PanOptica, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Pfenex Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Pfizer Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Precision Ocular Ltd, H1 2016
  • Age Related Macular Degeneration - Pipeline by Promedior, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by pSivida Corp., H1 2016
  • Age Related Macular Degeneration - Pipeline by QLT Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Ra Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by RegenxBio Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Ribomic Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by SanBio, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by SciFluor Life Sciences, LLC, H1 2016
  • Age Related Macular Degeneration - Pipeline by Sirnaomics, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Stealth BioTherapeutics Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Tyrogenex, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by VasGene Therapeutics, Inc., H1 2016
  • Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corporation, H1 2016
  • Age Related Macular Degeneration - Pipeline by Xbrane Biopharma AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Age Related Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2016
  • Age Related Macular Degeneration - Dormant Projects, H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..1), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..2), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..3), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..4), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..5), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..6), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..7), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..8), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..9), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..10), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..11), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..12), H1 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..13), H1 2016
  • Age Related Macular Degeneration - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Age Related Macular Degeneration, H1 2016
  • Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top